Immunoassay Reagent Advia Centaur® SARS-CoV-2 Antigen For Advia Centaur XP / Centaur XPT Immunoassay Systems 100 Tests
11207866 | USAMP#73036081
container type
Secure Checkout
Verified Supply Chain
Priority Fulfillment
Locked
Base Price
$1,885.08
KT
🎯 Unlock Your Custom Tiered Price
15-35% bulk discounts
100+
units
10% OFF
$XX.XX
per unit
Save $XXX
Payment Terms
Priority Shipping
Custom Contract Pricing
250+
units
20% OFF
$XX.XX
per unit
Save $XXX
Payment Terms
Priority Shipping
Custom Contract Pricing
500+
units
30% OFF
$XX.XX
per unit
Save $XXX
Payment Terms
Priority Shipping
Custom Contract Pricing
Unlock Bulk Pricing
See pricing for all volume tiers
Instant access to volume pricing. Register free to compare all tiers and calculate your exact savings.
5,000+ verified buyers
Average savings:$23,400/year
15-35% OFF
for healthcare facilities on bulk orders
24/7 Live Chat!
Instant support anytime
Product Spotlight
- ADVIA Centaur SARS-CoV-2 Antigen (CoV2Ag) assay is only for use under the Food and Drug Administration’s Emergency Use Authorization: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
- The ADVIA Centaur® SARS-CoV-2 Antigen (CoV2Ag) assay is a chemiluminescent immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in anterior nasal (AN) swab specimens collected in Siemens Healthineers Sample Inactivation Media, from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset, using the ADVIA Centaur® XP and ADVIA Centaur® XPT systems
- Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet the requirements to perform moderate or high complexity tests
- The ADVIA Centaur SARS-CoV-2 Antigen assay does not differentiate between SARS-CoV and SARS-CoV-2
- Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status; positive results do not rule out bacterial infection or co-infection with other viruses
- Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
- Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management may be performed; negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
- Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19
- The ADVIA Centaur SARS-CoV-2 Antigen (CoV2Ag) assay is intended for use by trained clinical laboratory personnel specifically instructed and trained in in vitro diagnostic procedures and proper infection control procedures
- Kit contains: 1 ReadyPack primary reagent pack containing ADVIA Centaur CoV2Ag Lite Reagent and Solid Phase, 1 ReadyPack ancillary reagent pack containing ADVIA Centaur CoV2Ag Ancillary Reagent, and ADVIA Centaur CoV2Ag master curve card
- The following materials are required to perform these assays, but are not provided: 11208047 ADVIA Centaur CoV2Ag CAL (calibrator), 11207868 ADVIA Centaur CoV2Ag QC (quality control material), 11208651 Sample Inactivation Media (inactivation reagent), 03395373 ADVIA Centaur Ancillary Probe Wash 1 (probe wash), 03333963 ADVIA Centaur Probe Wash 3 (probe wash), 01137199 (112351) ADVIA Centaur Wash 1 (wash), 03773025 ADVIA Centaur Wash 1 (wash)
